Bayer
This article was originally published in The Tan Sheet
Executive Summary
Combined Bayer aspirin, Aleve and Midol sales make firm second-largest analgesic marketer in U.S. and One-A-Day Specialized Blends is top branded herbal product, company tells analysts March 20. Global Consumer Care division sales rose 14.3% to $1.78 bil. in 2000, of which almost half came from North America, Bayer says. Consumer Care growth driven by increased sales of Alka-Seltzer, Bayer aspirin, Phillips' Milk of Magnesia and launch of Aleve Cold & Sinus. PPA-related recall of Alka-Seltzer Plus caused $53.7 mil. charge, in line with expectations (1"The Tan Sheet" Dec. 4, 2000, In Brief). Total worldwide sales grew 13.4% to $28.65 bil. as net income dipped 9.3% to $1.68 bil
You may also be interested in...
Alka-Seltzer Plus
Withdrawal of PPA-containing cold medicines estimated to cost Bayer [Euro]60 mil. to [Euro]80 mil. ($50.9 mil. to $67.9 mil), company says during recent analysts conference. The Alka-Seltzer Plus brand was heavily impacted by FDA's Nov. 3 letter requesting that manufacturers voluntarily discontinue marketing drugs containing phenylpropanolamine. All six effervescent products in the cough/cold line contain PPA; the five Liqui-Gel products are PPA free. Bayer says it hopes to introduce reformulated effervescent products in early 2001 (1"The Tan Sheet" Nov. 13, p. 4)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands